Please turn JavaScript on
Proactive - Interviews for investors icon

Proactive - Interviews for investors

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  3.88 / day

Message History

Pennpetro Energy plc (LSE:PPP) executive co-chairman and president of ICE Holdings Richard Spinks spoke with Proactive's Stephen Gunnion about the first commercial production of ICE black pellets, initial shipments to Poland and plans to expand capacity. Spinks said the first full production run was completed on October 29, with the pellets bagged and shipped to Poland. A test ...

Read full story
Silver Range Resources CEO Mike Power joined Steve Darling from Proactive to discuss results from a three-dimensional induced polarization (3D-IP) and resistivity survey at the company’s East Goldfield Property in Nye County, Nevada. The survey identified a large zone of elevated chargeability associated with surface lithocap and ledge-style epithermal high-sulphidation mineral...

Read full story
ertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) managing director Richard Belcher talked with Proactive's Stephen Gunnion about encouraging Phase 4 drilling results at its Mushima North project in Zambia, the start of deeper drilling and plans for a maiden mineral resource before year-end. The latest results confirmed wide, near-surface silver, copper and zinc intersections ...

Read full story
Hive Digital Technologies CEO Aydin Kilic joined Steve Darling from Proactive to discuss the company's second-quarter fiscal 2027 results for the three months ended September 30, 2026, highlighting growth in its high-performance computing (HPC) business and continued expansion of its global power capacity. HIVE reported revenue of $84.9 million, an increase of 7.3% sequentially...

Read full story
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug conjugate licensed from Pfizer. For the three months ended September 30, 2026, Medicus reporte...

Read full story